logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

    FiltersReset Filters
    6 results

    • bosulif

      (Bosutinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: BOSULIF is indicated for treating chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in adults and patients aged 1 and older, whether newly diagnosed or resistant/intolerant to prior therapies. It is also used for adult patients with accelerated or blast phases of Ph+ CML who are resistant/intolerant to prior treatments.

    • gleevec

      (imatinib mesylate)
      Novartis Pharmaceuticals Corporation
      Usage: This drug is indicated for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML), various phases of CML after interferon therapy, relapsed or refractory acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors (GIST).

    • imatinib mesylate

      (IMATINIB MESYLATE)
      Camber Pharmaceuticals, Inc.
      Usage: This drug is indicated for the treatment of newly diagnosed Philadelphia positive chronic myeloid leukemia (Ph+ CML), blast crisis, and acute lymphoblastic leukemia (ALL) in adults and pediatrics, as well as for myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.

    • imatinib mesylate

      (Imatinib Mesylate)
      Chartwell RX, LLC
      Usage: This drug is indicated for treatment of Philadelphia positive chronic myeloid leukemia (CML) in various phases, acute lymphoblastic leukemia (ALL), myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome, chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit+ gastrointestinal stromal tumors (GIST).

    • sprycel

      (dasatinib)
      E.R. Squibb & Sons, L.L.C.
      Usage: SPRYCEL (dasatinib) is indicated for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML), resistant or intolerant Ph+ CML, and Ph+ acute lymphoblastic leukemia (ALL). It also treats pediatric patients aged 1 and older with Ph+ CML and newly diagnosed Ph+ ALL with chemotherapy.

    • tasigna

      (nilotinib)
      Novartis Pharmaceuticals Corporation
      Usage: Tasigna is indicated for treating newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in adults and pediatric patients (≥1 year). It is also used for adults and pediatric patients with resistant or intolerant Ph+ CML in chronic or accelerated phases after prior tyrosine-kinase inhibitor therapy.